Product Images Losartan Potassium

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 6 images provide visual information about the product associated with Losartan Potassium NDC 51655-795 by Northwind Pharmaceuticals, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Label - 51655 795 26 Master Bottle Label Approval Rev A 01 22

Label - 51655 795 26 Master Bottle Label Approval   Rev A 01 22

This is a description of a 90-tablet bottle of Losartan Potassium tablets, USP, each of which contains 50mg of the active ingredient. The NDC code is 51655-795-26 and it is repackaged by Northwind Pharmaceuticals in Indianapolis. The LCN# is 00 and the Rev. A01/22. The tablets should be stored at room temperature, between 20°C and 25°C, with permitted excursions to between 15°C and 30°C. The expiry date is given as 00/00/0000 and the lot number is 0000000000. The package insert and dosage information are not provided.*

Figure1 - losartan fig1

Figure1 - losartan fig1

This appears to be a graph or chart with labels for two different medications, Atenolol and Losartan Potassium. It also includes a measure of "Adjusted Risk Reduction" and a progression of months (6-66). Without further context or the ability to view the graph/chart, it is difficult to provide a more specific description or interpretation.*

Figure2 - losartan fig2

Figure2 - losartan fig2

This appears to be a chart or table showing the percentage of patients experiencing fatal or non-fatal stroke while taking Atenolol or Losartan Potassium over a 66-month study period. No further information or context is provided, so it is difficult to interpret the results or make recommendations based on the data presented.*

Figure 3 - losartan fig3

Figure 3 - losartan fig3

The provided text is a table or figure containing data on the primary endpoint events for different demographic subgroups. The subgroups are identified by age, gender, race, and history of VD. The table shows the number or percentage of events for each subgroup compared to the overall results. There are also some unclear or unrecognizable characters and phrases in the text.*

Figure-4 - losartan fig4

Figure-4 - losartan fig4

This appears to be a table displaying the percentage of patients with an event for two different treatments, Losttan Potassium and placebo. The table also shows a risk reduction of 16.1% and a p-value of 0.022. Without further context, it is not clear what event is being referred to or what study this table is taken from.*

Chemical Structure - losartan str

Chemical Structure - losartan str

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.